MehmetKocogluMD

Physician

Dr. Kocoglu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-2632

Fax+1 410-328-6896

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2003 - 2006
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1999 - 1999
Hacettepe University FOMClass of 1996

PubMed

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-02-18
8 citations
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu
Blood. 2025-01-02
CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant.
David T Chen, Olga Goloubeva, Aaron P Rapoport, Saurabh Dahiya, Djordje Atanackovic
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-02

Abstracts/Posters

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Mehmet Hakan Kocoglu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...
Mehmet Hakan Kocoglu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019